publication date: Jan. 31, 2020

SU2C initiatives aim to boost diversity in cancer trials

By Alexandria Carolan

Stand Up To Cancer has launched two initiatives to increase minority representation in cancer clinical trials by amending its grant application requirements and funding a new research team focused on diversity and inclusion.

SU2C has developed the procurement language to solicit proposals for SU2C Dream Teams, Research Teams and other grants mechanisms in the SU2C research portfolio to increase diverse participation in cancer clinical trials.

Grant applicants submitted to SU2C will now need to include the following information:

An indication of whether the research will address the populations expected to benefit from widespread use of newly developed treatments;

Patient recruitment and retention plans for including historically underrepresented racial and ethnic populations—such as the need for additional trial sites or mechanisms to reduce barriers to access; and

A letter of support from the lead institution’s chief diversity officer, or an equivalent position.

These changes, announced at SU2C’s Scientific Summit Jan. 27, will also be considered in SU2C’s selection process, and as part of grant performance evaluation conducted in SU2C’s formal semi-annual reviews.

In U.S. cancer clinical trials in 2018, 4% of participants were black or African American, 4% were Hispanic, and 15% were Asian, according to data from FDA.

“We’re looking for a positive way for grantors to show a specific plan of how they’re going to recruit and retain minority populations in clinical trials,” John Whyte, SU2C committee member and chief medical officer of WebMD, said to The Cancer Letter. “FDA requirements say you should create a plan as to how you’re going to recruit minority populations, but no … Continue reading SU2C initiatives aim to boost diversity in cancer trials

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.